Novavax's Shares Rise as EU Authorizes Updated Nuvaxovid COVID-19 Vaccine Targeting JN.1 Strain

Oct 9, 2024, 12:30 PM

Novavax Inc.'s updated 2024-2025 Nuvaxovid COVID-19 vaccine has received authorization from the European Commission, the company announced on Wednesday. The vaccine, which targets the JN.1 strain of the coronavirus, is approved for preventing COVID-19 in individuals aged 12 years and older across the European Union. Following the news, Novavax's shares rose 3.2% in premarket trading.